FIGURE 2.
Cumulative mortality (with shaded 95% confidence intervals) from second cancers among patients treated on randomized clinical trials of dexrazoxane (P9404, 9425, 9426, and DFCI 95–01) by dexrazoxane (DRZ) status. Numbers at risk for mortality shown in Figure 1.